ProMIS Neurosciences Equity 2024

ProMIS Neurosciences Aktienanalyse

What does ProMIS Neurosciences do?

ProMIS Neurosciences Inc is a biopharmaceutical company based in Canada that specializes in the discovery and development of novel therapeutics for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The company was founded in 2004 and has been listed on the Toronto Stock Exchange since 2015. The goal of ProMIS is to develop highly specific therapeutics that specifically target the cellular causes of neurodegenerative diseases and can therefore stop or even reverse the progression of the disease. The company utilizes its proprietary platform technology to identify the unique epitopes on the pathological proteins that are specific to neurodegenerative diseases. ProMIS' business model is based on partnerships with large pharmaceutical companies that are searching for new therapeutics for neurodegenerative diseases. ProMIS works closely with these partners to develop customized therapeutics tailored to each partner's specific needs. The company licenses its technology and products to its partners and receives license and milestone payments when certain development or sales goals are achieved. ProMIS has different divisions to focus on various neurodegenerative diseases, with a focus on Alzheimer's, Parkinson's, and ALS. ProMIS has a comprehensive research and development infrastructure that focuses on the identification, characterization, and optimization of therapeutic antibodies and biomarkers. In terms of products, ProMIS has developed various antibodies that specifically target pathological proteins such as Aß and Tau in Alzheimer's and alpha-synuclein in Parkinson's. These antibodies can selectively recognize and bind to these pathological proteins, allowing them to be broken down and removed from the body. ProMIS works closely with its partners to test these antibodies in clinical trials and eventually bring them to market. In addition to its antibody products, ProMIS has also developed neuromethods that allow researchers to characterize and quantify the functions of proteins in brain cells and in vivo. These methods can be used to test and optimize the effects of antibodies and other therapeutics, making them an important part of ProMIS' development infrastructure. Overall, ProMIS Neurosciences Inc is an innovative biopharmaceutical company that focuses on the development of highly specific therapeutics for neurodegenerative diseases. The company has a comprehensive infrastructure and technology platform that allows it to develop customized products for its partners. With its antibodies and neuromethods, ProMIS has the potential to make a breakthrough in the treatment of neurodegenerative diseases and improve the lives of millions of patients. ProMIS Neurosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing ProMIS Neurosciences's Equity

ProMIS Neurosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding ProMIS Neurosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating ProMIS Neurosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

ProMIS Neurosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in ProMIS Neurosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about ProMIS Neurosciences stock

What is the equity of ProMIS Neurosciences this year?

ProMIS Neurosciences has equity of -1.35 M CAD this year.

What was the equity of ProMIS Neurosciences compared to the previous year?

The equity of ProMIS Neurosciences has increased/decreased by -123.81% decreased compared to the previous year.

What impact does a high equity have on investors of ProMIS Neurosciences?

A high equity is advantageous for investors of ProMIS Neurosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of ProMIS Neurosciences?

A low equity can be a risk for investors of ProMIS Neurosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of ProMIS Neurosciences affect the company?

An increase in equity of ProMIS Neurosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of ProMIS Neurosciences affect the company?

A reduction in equity of ProMIS Neurosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of ProMIS Neurosciences?

Some factors that can affect the equity of ProMIS Neurosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of ProMIS Neurosciences so important for investors?

The equity of ProMIS Neurosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can ProMIS Neurosciences take to change the equity?

To change equity, ProMIS Neurosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does ProMIS Neurosciences pay?

Over the past 12 months, ProMIS Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProMIS Neurosciences is expected to pay a dividend of 0 CAD.

What is the dividend yield of ProMIS Neurosciences?

The current dividend yield of ProMIS Neurosciences is .

When does ProMIS Neurosciences pay dividends?

ProMIS Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProMIS Neurosciences?

ProMIS Neurosciences paid dividends every year for the past 0 years.

What is the dividend of ProMIS Neurosciences?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProMIS Neurosciences located?

ProMIS Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProMIS Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProMIS Neurosciences from 11/4/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 11/4/2024.

When did ProMIS Neurosciences pay the last dividend?

The last dividend was paid out on 11/4/2024.

What was the dividend of ProMIS Neurosciences in the year 2023?

In the year 2023, ProMIS Neurosciences distributed 0 CAD as dividends.

In which currency does ProMIS Neurosciences pay out the dividend?

The dividends of ProMIS Neurosciences are distributed in CAD.